MRTX1133 can be an extremely potent and selective KRASG12D inhibitor. It optimally fills the change II pocket and extends a few substituents to favorably interact with the protein. The K An additional prospective advantage of combining KRAS inhibitors and checkpoint inhibitors is these drugs